In a 50‑year‑old woman with estrogen‑receptor‑positive invasive ductal carcinoma (node‑negative, Oncotype DX score 7) on an aromatase inhibitor who now has widespread fasciculations, mild weight gain, dyspnea, dysphagia‑like sensation, exercise‑induced peripheral tingling, and a normal neurologic exam, is an ALS workup indicated?

No ALS Workup Is Needed

In this 50-year-old woman with ER+ invasive ductal carcinoma on aromatase inhibitor therapy presenting with fasciculations, mild weight gain, dyspnea, dysphagia-like sensation, exercise-induced peripheral tingling, and a completely normal neurologic exam, an ALS workup is not indicated.

Clinical Reasoning

Why ALS Is Extremely Unlikely

The clinical presentation fundamentally contradicts the diagnostic criteria for ALS:

• Normal neurologic examination is incompatible with ALS - ALS requires objective findings of both upper motor neuron signs (hypertonicity, hyperreflexia) and lower motor neuron signs (muscle weakness, atrophy) 1
• Fasciculations alone are not diagnostic - They must occur in the context of progressive muscle weakness and atrophy
• Symptom pattern doesn't fit - ALS typically presents with focal, progressive weakness spreading to contiguous regions, not diffuse sensory symptoms like tingling

The Real Culprit: Aromatase Inhibitor Side Effects

This symptom constellation is entirely consistent with known aromatase inhibitor adverse effects:

Musculoskeletal symptoms are among the most common side effects of aromatase inhibitors 2:

• Muscle cramps and fasciculations
• Arthralgias and myalgias
• Exercise intolerance

Weight changes occur with hormonal manipulation 2

Dyspnea and dysphagia-like sensations may represent:

• Anxiety related to cancer diagnosis and treatment
• Musculoskeletal chest wall discomfort
• Gastroesophageal symptoms (common with aromatase inhibitors)

Peripheral tingling suggests chemotherapy-induced peripheral neuropathy (CIPN), though the Oncotype DX score of 7 makes prior chemotherapy unlikely 3

Diagnostic Approach

What You Should Do Instead:

1. Reassess aromatase inhibitor tolerance

   • Document timing of symptom onset relative to AI initiation
   • Consider switching between non-steroidal (anastrozole, letrozole) and steroidal (exemestane) AIs if symptoms are intolerable

2. Evaluate for peripheral neuropathy if tingling persists 3:

   • Clinical sensory examination
   • Consider nerve conduction studies only if examination is abnormal
   • Rule out other causes: diabetes, B12 deficiency, thyroid dysfunction

3. Address dysphagia symptoms:

   • If persistent or worsening, consider upper endoscopy
   • Evaluate for reflux disease
   • Rule out mechanical obstruction

4. Monitor for red flags that would change the assessment:

   • Development of objective weakness on examination
   • Progressive, asymmetric muscle atrophy
   • Pathologic hyperreflexia with upgoing toes
   • Bulbar dysfunction with tongue fasciculations and atrophy

Common Pitfalls to Avoid

Don't order unnecessary testing based on subjective symptoms alone - The normal neurologic exam is your most important finding. ALS workup (EMG/NCS, MRI spine) is invasive, expensive, and will be negative 1.

Don't dismiss patient concerns - Validate the symptoms while explaining they don't fit a neurodegenerative pattern. Many cancer patients experience health anxiety that manifests as hypervigilance about symptoms.

Don't overlook medication side effects - With an Oncotype DX score of 7 (very low risk), this patient is receiving appropriate endocrine-only therapy 4, 5. The benefits of continuing AI therapy far outweigh the nuisance of these symptoms, but symptom management is important for adherence.

When to Reconsider

Revisit the diagnosis only if:

• Objective weakness develops on serial examinations
• Fasciculations become associated with visible muscle atrophy
• Upper motor neuron signs emerge (hyperreflexia, spasticity, Babinski sign)
• Symptoms progress despite discontinuing the aromatase inhibitor

The normal neurologic examination effectively rules out ALS at this time 1.